Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Receivables (2020 - 2025)

Bioventus' Receivables history spans 6 years, with the latest figure at $131.4 million for Q4 2025.

  • For Q4 2025, Receivables rose 3.07% year-over-year to $131.4 million; the TTM value through Dec 2025 reached $131.4 million, up 3.07%, while the annual FY2025 figure was $131.4 million, 3.07% up from the prior year.
  • Receivables reached $131.4 million in Q4 2025 per BVS's latest filing, up from $130.4 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $155.4 million in Q4 2021 to a low of $89.5 million in Q2 2021.
  • Average Receivables over 5 years is $126.9 million, with a median of $127.4 million recorded in 2023.
  • Peak YoY movement for Receivables: soared 40.17% in 2022, then decreased 18.21% in 2023.
  • A 5-year view of Receivables shows it stood at $125.0 million in 2021, then grew by 9.21% to $136.6 million in 2022, then fell by 6.81% to $127.3 million in 2023, then grew by 0.16% to $127.5 million in 2024, then grew by 3.07% to $131.4 million in 2025.
  • Per Business Quant, the three most recent readings for BVS's Receivables are $131.4 million (Q4 2025), $130.4 million (Q3 2025), and $135.3 million (Q2 2025).